Glofitamab in relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) : durable complete responses and manageable safety observed at clinically relevant doses in Phase I dose escalation

Authors
Publication date
1 January 2020
Publisher

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Ghent University Academic Bibliography

    redirect
    oaioai:archive.ugent.be:8693910
    Last time updated on 10/04/2021